The NXF3 Monoclonal Antibody (PACO28682) is a valuable tool for researchers studying NXF3, a key protein involved in mRNA nuclear export. This antibody, produced using hybridoma technology, is highly specific for human NXF3 and has been validated for use in various applications, including immunofluorescence and flow cytometry.NXF3 is essential for the export of processed mRNA from the nucleus to the cytoplasm, playing a crucial role in gene expression regulation.
Dysregulation of NXF3 has been linked to various diseases, including cancer and neurological disorders, making it an attractive target for further investigation. By utilizing the NXF3 Monoclonal Antibody, researchers can gain valuable insights into the function and localization of NXF3 in different cell types, aiding in the advancement of molecular biology and disease research.
NXF3: May function as a tissue-specific nuclear mRNA export factor. Belongs to the NXF family.Chromosomal Location of Human Ortholog: Xq22Cellular Component: cytoplasm; nuclear RNA export factor complex; nucleoplasm; nucleusMolecular Function: mRNA binding; nucleotide binding; protein bindingBiological Process: mRNA export from nucleus; poly(A)+ mRNA export from nucleus
UniProt Protein Details:
NCBI Summary:
This gene is one member of a family of nuclear RNA export factor genes. Common domain features of this family are a noncanonical RNP-type RNA-binding domain (RBD), 4 leucine-rich repeats (LRRs), a nuclear transport factor 2 (NTF2)-like domain that allows heterodimerization with NTF2-related export protein-1 (NXT1), and a ubiquitin-associated domain that mediates interactions with nucleoporins. The LRRs and NTF2-like domains are required for export activity. Alternative splicing seems to be a common mechanism in this gene family. The encoded protein of this gene has shortened LRR and ubiquitin-associated domains and its RDB is unable to bind RNA. It is located in the nucleoplasm but is not associated with either the nuclear envelope or the nucleolus. [provided by RefSeq, Jul 2008]